Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Pathologically proven non-small cell lung cancer (NSCLC)
• * Stage IA-IIIB disease
• Underwent prior complete surgical resection (R0) no more than 2 months ago
• Eligible for cisplatin-based adjuvant chemotherapy
• PATIENT CHARACTERISTICS:
• Karnofsky performance status ≥ 70%
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hemoglobin ≥ 8.0 g/dL
• Platelet count ≥ 100,000/mm\^3
• Creatinine clearance \> 55 mL/min
• Total bilirubin normal
• Alkaline phosphatase, AST, and ALT must meet 1 of the following criteria:
• * Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
• * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
• * AP ≤ 5 times ULN AND AST and ALT normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after completion of study treatment
• No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
• No peripheral neuropathy \> grade 1
• No hearing deficit at baseline, even if it does not require a hearing aid or intervention or interfere with activities of daily life (i.e., CTCAE grade 2 or higher)
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior postoperative radiation therapy
• No prior chemotherapy for NSCLC
• No prior docetaxel or cisplatin
• No concurrent prophylactic filgrastim (G-CSF) or pegfilgrastim